These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 8938284)

  • 1. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
    Dietrich W
    J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S50-7. PubMed ID: 8938284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study.
    Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA
    Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
    Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
    Koster A; Huebler S; Merkle F; Hentschel T; Gründel M; Krabatsch T; Tambeur L; Praus M; Habazettl H; Kuebler WM; Kuppe H
    Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
    Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
    Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
    Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
    Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system.
    Rossi M; Storti S; Martinelli L; Varano C; Marra R; Zamparelli R; Possati G; Schiavello R
    J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):835-9. PubMed ID: 9412880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clotting and fibrinolytic disturbance during lung transplantation: effect of low-dose aprotinin. Groningen Lung Transplant Group.
    Gu YJ; de Haan J; Brenken UP; de Boer WJ; Prop J; Van Oeveren W
    J Thorac Cardiovasc Surg; 1996 Sep; 112(3):599-606. PubMed ID: 8800145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
    Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
    Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass.
    Chan AK; Leaker M; Burrows FA; Williams WG; Gruenwald CE; Whyte L; Adams M; Brooker LA; Adams H; Mitchell L; Andrew M
    Thromb Haemost; 1997 Feb; 77(2):270-7. PubMed ID: 9157580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery.
    Knudsen L; Hasenkam JM; Kure HH; Hughes P; Bellaiche L; Ahlburg P; Djurhuus C
    Thromb Res; 1996 Oct; 84(1):45-54. PubMed ID: 8885146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation.
    Grossmann R; Babin-Ebell J; Misoph M; Schwender S; Neukam K; Hickethier T; Elert O; Keller F
    Heart Vessels; 1996; 11(6):310-7. PubMed ID: 9248850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery.
    Baufreton C; Velthuis HT; Jansen PG; Besnerais PL; Wildevuur CH; Loisance DY
    ASAIO J; 1996; 42(5):M417-23. PubMed ID: 8944919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing hemostatic activation during cardiopulmonary bypass: a combined approach.
    Eisses MJ; Seidel K; Aldea GS; Chandler WL
    Anesth Analg; 2004 May; 98(5):1208-16, table of contents. PubMed ID: 15105189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
    Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
    Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations.
    te Velthuis H; Baufreton C; Jansen PG; Thijs CM; Hack CE; Sturk A; Wildevuur CR; Loisance DY
    J Thorac Cardiovasc Surg; 1997 Jul; 114(1):117-22. PubMed ID: 9240301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.